Tech Company Financing Transactions

Prexa Pharmaceuticals Funding Round

Synthesis Capital, Shire Pharmaceuticals and private investors participated in a $7 million Series B capital raise for Prexa Pharmaceuticals. The financing was recorded on 5/11/2011.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

184 High St.
Boston, MA 02110
USA

Phone

617-780-1443

Website

www.prexainc.com

Email Address

[email protected]

Overview

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson's disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Charlie Cohen

        

Chief Medical Officer

Scott Reines

        

Chief Operating Officer

Evelyn Graham

        

Chief Technical Officer

Philip Huxley

        

Browse more venture capital transactions:

Prev: 5/11/2011: Inporia venture capital transaction
Next: 5/11/2011: Airtime venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary